Web1 day ago · The MarketWatch News Department was not involved in the creation of this content. Apr 13, 2024 (The Expresswire) -- The "Immobilization Products Market" Size, Trends and Forecasts (2024-2030)â ... Web1 day ago · The MarketWatch News Department was not involved in the creation of this content. Apr 13, 2024 (The Expresswire) -- The "Immobilization Products Market" Size, …
Equillium Acquires Bioniz Therapeutics Significantly Expanding …
WebAug 4, 2024 · Bioniz conducted a Phase 1/2 study in CTCL, in which BNZ-1 exhibited a major improvement in safety and efficacy relative to standard of care. On the strength of … WebApr 9, 2024 · 2024年2月16日,Equillium公司宣布收购Bioniz Therapeu- 期临床试验的准备,计划在乳糜泻患者中进行概念验证评估。 tics。Bioniz的先导候选产品是同时靶向经临床验证的多个疾 BNZ-2目前配方用于皮下给药,旨在解决尝试维持无麸质饮食 bakari malik
Equillium - Equillium Acquires Bioniz Therapeutics
WebLegal Name Bioniz, Llc. Company Type For Profit. Contact Email [email protected]. Phone Number (949)273-6000. Bioniz is an emerging biotechnology/drug development company focused on discovering small peptides and molecules for the treatment of autoimmune diseases and some forms of cancer. Bioniz mission is to complete proof of … WebMay 12, 2024 · About Bioniz's Pipeline of Multi-Cytokine Inhibitors Bioniz recently completed a phase 2 study of the Company's lead product candidate, BNZ-1, in cutaneous T-cell lymphoma (CTCL) and is planning a ... WebDec 5, 2024 · IRVINE, Calif., Dec. 5, 2024 /PRNewswire/ -- Bioniz Therapeutics, Inc., ("Bioniz") today announced positive clinical data in an oral presentation at the 62nd ASH Annual Meeting And Exposition from the company's Phase 1/2 clinical study of BNZ-1 for the treatment of patients with relapsed or refractory cutaneous T-cell lymphoma (rCTCL), a … aranyam attar